Mayo code ENS2 Evaluating new onset encephalopathy (noninfectious or metabolic) comprising confusional states, psychosis, delirium, memory loss, hallucinations, movement disorders, sensory or motor complaints, seizures, dyssomnias, ataxias, nausea, vomiting, inappropriate antidiuresis, coma, dysautonomias, or hypoventilation in serum specimens
The following accompaniments should increase of suspicion for autoimmune encephalopathy: -Headache -Autoimmune stigmata (personal or family history or signs of diabetes mellitus, thyroid disorder, vitiligo, poliosis [premature graying], myasthenia gravis, rheumatoid arthritis, systemic lupus erythematosus) -History of cancer -Smoking history (20+ pack years) or other cancer risk factors -Inflammatory cerebral spinal fluid (or isolated protein elevation) -Neuroimaging signs suggesting inflammation
Evaluating limbic encephalitis (noninfectious)
Directing a focused search for cancer
Investigating encephalopathy appearing in the course or wake of cancer therapy and not explainable by metastasis or drug effect
Specimen Type
Blood
Container
Red Top Tube
Collection Instructions
Container/Tube: Gold Top or Red Top Tube Specimen: 4.0 mL serum (2.5 mL min)
Patient Preparation: 1. For optimal antibody detection, specimen collection is recommended prior to initiation of immunosuppressant medication or intravenous immunoglobulin treatment. 2. This test should not be requested in patients who have recently received radioisotopes, therapeutically or diagnostically, because of potential assay interference. The specific waiting period before specimen collection will depend on the isotope administered, the dose given, and the clearance rate in the individual patient. Specimens will be screened for radioactivity prior to analysis. Radioactive specimens received in the laboratory will be held 1 week and assayed if sufficiently decayed, or canceled if radioactivity remains. 3. Patient should have no general anesthetic or muscle-relaxant drugs in the previous 24 hours.
Transport Instructions
Refrigerated
Specimen Stability
72 Hours Room Temperature 28 Days Refrigerated or Frozen
Methodology
Indirect Immunofluorescence Assay (IFA) Cell-Binding Assay (CBA) Western Blot (WB) Immunoblot (IB) Radioimmunoassay (RIA)
Days Performed
TAT: 9-13 Days
Performing Laboratory
Mayo Clinic Laboratories in Rochester
CPT
86255 x 23 86341 LOINC Code: 94697-0
PDM
1759374
Results
Component Name
Base Name
Common Name
External Name
GLUTAMIC ACID DECARBOXYLASE ANTIBODY
GADAB
GLUTAMIC ACID DECARB AB
ENCEPHALOPATHY, INTERPRETATION, S
ENCEPINTRPS
ENCEP INTERP S
Encephalopathy, Interpretation, S
DIPEPTIDYL AMINOPEPTIDASE-LIKE PROTEIN 6 AB IGG
DPPXABIFA
DIPEPTIDYL AMINOPEPTIDASE LIKE PROTEIN 6 AB IGG
Dipeptidyl aminopeptidase-like protein 6 AB IGG
NEUROCHONDRIN AB
NEUROCHIFA
NEUROCHONDRIN AB
Neurochondrin AB
NMDA-R AB CBA, CSF
NMDARABCBA
NMDA R AB CBA, CSF
Nmda-R Ab Cba, Csf
ANNA-3, S
ANNA3S
ANNA 3 S
Anna-3, S
GABA-B- RECEPTOR ANTIBODY BY CBA, SERUM
GABABABCBA
GABA B ABCBA
Gaba-B- Receptor Antibody By Cba, Serum
REFLEX ADDED
REFADD
REFLEX ADDED
Reflex Added
CRMP-5-IGG WESTERN BLOT
CR5IGWESBLOT
CR 5 IGG WES BLOT
Crmp-5-Igg Western Blot
ANNA-2, S
ANNA2S
ANNA 2 S
Anna-2, S
AMPHIPHYSIN AB, S
AMPHIPABS
AMPHIP AB S
Amphiphysin Ab, S
NMDAR- ABCBAC
NMDARABCBAC
NMDAR ABCBAC
NMDAR- AbCBAC
PURKINJE CELL CYTOPLASMIC AB TYPE 1
PURCYTO1
PURKINJE CELL CYTOPLASMIC AB TYPE 1
Purkinje Cell Cytoplasmic Ab Type 1
AMPA-R ABCBA
AMPARABCBA
AMPA R ABCBA
Ampa-R Abcba
NEURONAL (V-G) K+ CHANNEL AB, S
VGKCHANAB
NEURONAL VOLTAGE GATED K CHANNEL AB
Neuronal (V-G) K+ Channel Ab, S
PCA-1, S
PCA1S
PCA 1 S
Pca-1, S
AGNA-1, S
AGNA1S
AGNA 1 S
Agna-1, S
GLIAL FIBRILLARY ACIDIC PROTEIN.ALPHA SUBUNIT AB IGG
GFAPIFA
GLIAL FIBRILLARY ACIDIC PROTEIN ALPHA SUBUNIT AB IGG
Glial Fibrillary Acidic Protein.Alpha Subunit Ab Igg
